Company Profile
Decipher Biosciences Stock Price, News & Analysis
- Ticker:
- DECI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for DECI.
Company overview
Business overview
Decipher Biosciences was a precision oncology diagnostics company focused on genomic tools for cancer risk and treatment selection before being acquired. Its story was rooted in molecular diagnostics and data-driven oncology decisions.
Geographic Base and Sector Classification
Decipher was headquartered in the United States and listed on NASDAQ before the acquisition. It sat in oncology diagnostics rather than therapeutics.
Business Model Characteristics
The company depended on diagnostic adoption, reimbursement, and the ability to make genomic testing clinically indispensable. Investors historically watched test utilization and strategic interest.
Position Within the Biotechnology Landscape
Decipher belongs to the historical precision-oncology diagnostics category. It is best thought of as a molecular-testing business that became valuable through strategic fit.
Future catalysts
Decipher Biosciences is now a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update. There is no active standalone growth story left.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Decipher Biosciences do?
Decipher Biosciences was a precision oncology diagnostics company focused on genomic tools for cancer risk and treatment selection before being acquired. Its story was rooted in molecular diagnostics and data-driven oncology decisions.
On which exchange is DECI stock listed?
Decipher Biosciences (DECI) is associated with NASDAQ, United States, Biopharma.
What is Decipher?
Decipher Biosciences is now a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update.
Which conditions is Decipher Biosciences targeting with Decipher?
Decipher Biosciences is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Decipher Biosciences describe recent progress with Decipher?
Decipher Biosciences is now a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update.
What is Biosciences?
Decipher Biosciences was a precision oncology diagnostics company focused on genomic tools for cancer risk and treatment selection before being acquired.
What should investors watch for with Biosciences?
Decipher Biosciences is now a legacy / closeout story, so the catalysts are any remaining strategic or asset-resolution update.
What is There?
There is no active standalone growth story left.